{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "atropine",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "2. DOSAGE AND ADMINISTRATION In individuals from three (3) months of age or greater, 1 drop topically to the cul-de-sac of the conjunctiva, forty minutes prior to the intended maximal dilation time ( 2.1 ) In individuals 3 years of age or greater, doses may be repeated up to twice daily as needed.",
        "source": "US FDA label for atropine (Atropine), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/atropine.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Due to the potential for systemic absorption of atropine sulfate ophthalmic solution, the use of atropine sulfate ophthalmic solution, 1% in children under the age of 3 months is not recommended and the use in children under 3 years of age should be limited to no more than one drop per eye per day.",
        "source": "US FDA label for atropine (Atropine), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/atropine.json",
        "verbatim": true
      },
      {
        "text": "2. DOSAGE AND ADMINISTRATION In individuals from three (3) months of age or greater, 1 drop topically to the cul-de-sac of the conjunctiva, forty minutes prior to the intended maximal dilation time ( 2.1 ) In individuals 3 years of age or greater, doses may be repeated up to twice daily as needed.",
        "source": "US FDA label for atropine (Atropine), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/atropine.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "No kidney-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for atropine (Atropine), retrieved 2026-08-29",
        "cached_file": "labels/atropine.json",
        "verbatim": false
      }
    ],
    "hepatic": [
      {
        "text": "No liver-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for atropine (Atropine), retrieved 2026-08-29",
        "cached_file": "labels/atropine.json",
        "verbatim": false
      }
    ],
    "pregnancy": [
      {
        "text": "Pregnancy Category C: There are no adequate and well-controlled studies of atropine sulfate in pregnant women.",
        "source": "US FDA label for atropine (Atropine), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/atropine.json",
        "verbatim": true
      },
      {
        "text": "Animal development and reproduction studies have not been conducted with atropine sulfate.",
        "source": "US FDA label for atropine (Atropine), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/atropine.json",
        "verbatim": true
      },
      {
        "text": "Since it is not known whether topically administered atropine sulfate can cause fetal harm, atropine sulfate ophthalmic solution, 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.",
        "source": "US FDA label for atropine (Atropine), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/atropine.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "Traces of atropine have been found in human milk following administration of atropine solution for injection.",
        "source": "US FDA label for atropine (Atropine), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/atropine.json",
        "verbatim": true
      },
      {
        "text": "Because some systemic absorption occurs from topical administration, caution should be exercised when atropine sulfate ophthalmic solution, 1% is administered to a nursing woman.",
        "source": "US FDA label for atropine (Atropine), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/atropine.json",
        "verbatim": true
      },
      {
        "text": "Since it is not known whether topically administered atropine sulfate can cause fetal harm, atropine sulfate ophthalmic solution, 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. 8.3 Nursing Mothers Traces of atropine have been found in human milk following administration of atropine solution for injection.",
        "source": "US FDA label for atropine (Atropine), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/atropine.json",
        "verbatim": true
      }
    ]
  }
}